Literature DB >> 24731848

Late-onset nonketotic hyperglycinemia with a heterozygous novel point mutation of the GLDC gene.

J Nicholas Brenton1, Robert S Rust2.   

Abstract

BACKGROUND: Atypical nonketotic hyperglycinemia is characterized by heterogeneous phenotypes that often include nonspecific behavioral problems, cognitive deficits, and developmental delays. PATIENT: We describe a girl with late-onset nonketotic hyperglycinemia presenting at 5 years of age with hypotonia, chorea, ataxia, and alterations in consciousness in the setting of febrile illness.
RESULTS: Serum amino acid analysis was mildly elevated; however, urine amino acid analysis was instrumental in demonstrating marked hyperglycinuria. Mutation testing showed a heterozygous novel sequence change/point mutation in the glycine decarboxylase gene.
CONCLUSIONS: This patient illustrates the importance of obtaining urine amino acids in individuals whose clinical manifestations are suspicious for any form of nonketotic hyperglycinemia, because this testing may provide more prominent evidence of elevations in glycine. She also illustrates the potential for a heterozygous mutation to result in manifestations of an atypical form of nonketotic hyperglycinemia.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chorea; developmental delay; encephalopathy; movement disorder; nonketotic hyperglycinemia

Mesh:

Year:  2014        PMID: 24731848     DOI: 10.1016/j.pediatrneurol.2014.01.018

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

1.  Novel compound heterozygous LIAS mutations cause glycine encephalopathy.

Authors:  Yoshinori Tsurusaki; Ryuta Tanaka; Shino Shimada; Keiko Shimojima; Masaaki Shiina; Mitsuko Nakashima; Hirotomo Saitsu; Noriko Miyake; Kazuhiro Ogata; Toshiyuki Yamamoto; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2015-06-25       Impact factor: 3.172

2.  The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT.

Authors:  Curtis R Coughlin; Michael A Swanson; Kathryn Kronquist; Cécile Acquaviva; Tim Hutchin; Pilar Rodríguez-Pombo; Marja-Leena Väisänen; Elaine Spector; Geralyn Creadon-Swindell; Ana M Brás-Goldberg; Elisa Rahikkala; Jukka S Moilanen; Vincent Mahieu; Gert Matthijs; Irene Bravo-Alonso; Celia Pérez-Cerdá; Magdalena Ugarte; Christine Vianey-Saban; Gunter H Scharer; Johan L K Van Hove
Journal:  Genet Med       Date:  2016-06-30       Impact factor: 8.822

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.